for individual wellbeing
IBSA Farmaceutici, founded in 1992, is part of IBSA (Institut Biochimique SA) and has its headquarters in Lodi, where the first production plant was born. Over the years, IBSA has grown rapidly, expanding its offices in Rome and its production facility in Cassina de’ Pecchi (Milan), and becoming a leading economic and scientific player in the Italian pharmaceutical sector.
Currently, IBSA employs over 500 people in Italy and holds 80 patent families on cutting-edge pharmaceutical technologies. Our interest in technology, scientific know-how and R&D investments have allowed the Company to build an extensive product portfolio covering 10 therapeutic areas. Drugs, medical devices and food supplements are developed and produced by IBSA people in Italy and sold in more than 90 countries worldwide. Specifically, the aesthetic medicine division of IBSA is the international reality bringing innovations for the aesthetic medicine, offering solutions with a high safety and efficacy profile. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility. Finally, the fifth pillar of the IBSA philosophy is Accessibility, which, together with Innovation, translates into the desire to develop solutions that allow consumers to access treatments that are today considered elite or that facilitates expert/patient interaction.
WHAT WE ARE LOOKING FOR
At the aesthetic medicine of IBSA, we value proposals engaging with the field of esthetics medicine, bringing the know-how and scientific experience of IBSA Farmaceutici into the theme of dermo-esthetics.
IBSA is aware of the needs of its customers and aims at expanding its role in the sector offering a wide range of products and options. The company directs the entire production chain of its offerings; from biofermentation of quality raw materials to the single vial. The realizations of our products, from research to commerciality, passes through the Made in Italy brand of which IBSA is a proud promoter.
IBSA is looking for new realities willing to pioneer a new approach to esthetics medicine, promoting inner, authentic beauty through top-quality and innovative solutions. IBSA will examine solutions in accordance with the company vision.
The aim of this call is to find innovative solutions with particular focus on:
- Solutions based on hyaluronic acid or other substances and technologies (e.g. laser, energy device) that promote tissue regeneration, with proven applicability in dermatology and/or aesthetics;
- Artificial intelligence solutions or other technologies applicable in the dermatology and/or aesthetics, including but not limited to those that aid in diagnosis or physician-patient interaction.
- Solutions aimed at women’s health and well-being in the pre- and post-menopausal age. In particular, solutions are sought in the field of dermatology and related to the urogenital apparatus.
IBSA is calling for solutions with particular focus on:
WHAT WILL YOU WIN
The organization(s) with the most suitable projects for the company’s interests will have the opportunity to integrate their proposal to IBSA’S medical solutions, to collaborate with a team of experts for developing new products and might obtain funding for their activities.
WHO CAN APPLY
The Call is open to researchers, start-ups, innovative SMEs, and universities proposing solutions and projects that are aligned with IBSA’s needs and respect the core requirements of its programmes: Person, Innovation, Quality and Responsibility.
Level of development of the solutions sought: greater importance is placed on the innovativeness and feasibility of the proposed solution, not only on its level of maturity. The call would also accept interesting solutions/products that are not already marketed but with a good/advanced level of development.
The project must comply with current normative standards and be economically feasible.
Applications can be submitted in English or Italian, they will be evaluated by Le Village CA Milan and by IBSA management.
To submit your solution, please complete the form below in full by no later than 23:59 (11:59 PM) on 15th of October.